Trinity Biotech (TRIB) Net Income towards Common Stockholders (2009 - 2024)

Trinity Biotech has disclosed Net Income towards Common Stockholders across 16 years of filings, most recently posting -$15.8 million for Q4 2024.

• Net Income towards Common Stockholders for Q4 2024 came in at -$15.8 million, down 187.11% year-over-year; the trailing twelve-month figure through Dec 2025 was -$20.6 million (up 33.13% YoY), and the FY2025 annual result was -$37.4 million, down 17.58% from the prior year.
• Net Income towards Common Stockholders came in at -$15.8 million for Q4 2024 at Trinity Biotech, down from -$4.8 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $10.7 million in Q3 2020 to a low of -$18.3 million in Q2 2023.
• The 5-year median for Net Income towards Common Stockholders is -$5.1 million (2023), against an average of -$4.2 million.
• Across the five-year window, Net Income towards Common Stockholders jumped 438.11% in 2020 and plunged 2026.0% in 2022, its largest moves.
• Trinity Biotech's Net Income towards Common Stockholders stood at $9.1 million in 2020, then sank by 138.52% to -$3.5 million in 2021, then tumbled by 186.25% to -$10.1 million in 2022, then jumped by 45.29% to -$5.5 million in 2023, then plunged by 187.11% to -$15.8 million in 2024.
• The last three Net Income towards Common Stockholders figures came in at -$15.8 million (Q4 2024), -$4.8 million (Q3 2024), and -$7.0 million (Q2 2024), per Business Quant data.